Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT

@article{Sawicki2017EvaluationO6,
  title={Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT},
  author={Lino Morris Sawicki and Cornelius Deuschl and Karsten J Beiderwellen and Verena Ruhlmann and Thorsten Dirk Poeppel and Philipp Heusch and Harald Lahner and D. J. Fuehrer and Andreas Bockisch and Ken Herrmann and Michael Forsting and Gerald Antoch and Lale Umutlu},
  journal={European Radiology},
  year={2017},
  volume={27},
  pages={4091-4099}
}
To compare the diagnostic performance of 68Ga-DOTATOC PET/MRI and 68Ga-DOTATOC PET/CT in the whole-body staging of patients with neuroendocrine tumours (NET). Thirty patients with histopathologically confirmed NET underwent PET/CT and PET/MRI in a single-injection protocol. PET/CT and PET/MRI scans were prospectively evaluated with regard to lesion count, localization, nature (NET/non-NET), and conspicuity (four-point scale). Histopathology and follow-up imaging served as the reference… CONTINUE READING